Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part D Coverage Could Lead To Drug Price Uniformity, Pfizer Exec Says

Executive Summary

Implementation of the Medicare Part D drug benefit could ultimately mean more uniform pricing across different market segments in the U.S., a Pfizer exec suggested Jan. 25

You may also be interested in...

“Best Price” Or Better? Medicare/Medicaid Rules May Confuse Rebates

CMS may need to intervene in Medicaid pharmacy reimbursement practices to ensure that the Medicare Part D program runs smoothly, Mintz Levin attorney Carolyn McElroy suggested Feb. 1 during CBI's Pharmaceutical Marketing Compliance Congress in Washington, D.C

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts